Amycretin Phase 2 trial (NCT06542874)
Safety and Efficacy of Once-weekly Subcutaneous and Once-daily Oral NNC0487-0111 in Participants With Type 2 Diabetes - a Dose Finding Study
Registry record checked
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 448
- actual
- Start
- 7 Aug 2024 (actual)
- Primary completion
- 1 Oct 2025 (actual)
- Sponsor
- Novo Nordisk A/S
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Placebo subcutaneous | Placebo comparator | Drug: Placebo (NNC0487-0111 subcutanous) | Placebo for subcutaneous treatment |
| NNC0487-0111 subcutaneous dose 1 | Experimental | Drug: NNC0487-0111 subcutanous | NNC0487-0111 subcutaneous dose 1 treatment |
| NNC0487-0111 subcutaneous dose 2 | Experimental | Drug: NNC0487-0111 subcutanous | NNC0487-0111 subcutaneous dose 2 treatment |
| NNC0487-0111 subcutaneous dose 3 | Experimental | Drug: NNC0487-0111 subcutanous | NNC0487-0111 subcutaneous dose 3 treatment |
| NNC0487-0111 subcutaneous dose 4 | Experimental | Drug: NNC0487-0111 subcutanous | NNC0487-0111 subcutaneous dose 4 treatment |
| NNC0487-0111 subcutaneous dose 5 | Experimental | Drug: NNC0487-0111 subcutanous | NNC0487-0111 subcutaneous dose 5 treatment |
| NNC0487-0111 subcutaneous dose 6 | Experimental | Drug: NNC0487-0111 subcutanous | NNC0487-0111 subcutaneous dose 6 treatment |
| Placebo oral | Placebo comparator | Drug: Placebo (NNC0487-0111 oral) | Placebo for oral treatment |
| NNC0487-0111 oral dose 1 | Experimental | Drug: NNC0487-0111 oral | NNC0487-0111 oral dose 1 treatment |
| NNC0487-0111 oral dose 2 | Experimental | Drug: NNC0487-0111 oral | NNC0487-0111 oral dose 2 treatment |
| NNC0487-0111 oral dose 3 | Experimental | Drug: NNC0487-0111 oral | NNC0487-0111 oral dose 3 treatment |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Change in HbA1c | From baseline (week 0) to end of treatment (week 36) |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Relative change in body weight | From baseline (week 0) to end of treatment (week 36) |
| Change in body weight | From baseline (week 0) to end of treatment (week 36) |
| Change in fasting plasma glucose (FPG) | From baseline (week 0) to end of treatment (week 36) |
| CGM: Change in time in range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL) | From baseline (week 0) to end of treatment (week 36) |
| Change in body mass index (BMI) | From baseline (week 0) to end of treatment (week 36) |
| Change in waist circumference | From baseline (week 0) to end of treatment (week 36) |
| Change in systolic blood pressure (SBP) | From baseline (week 0) to end of treatment (week 36) |
| Change in average 24-hour systolic blood pressure (SBP) | From baseline (week 0) to end of treatment (week 36) |
| Change in high sensitivity C-Reactive Protein (hsCRP) | From baseline (week 0) to end of treatment (week 36) |
| Change in total cholesterol | From baseline (week 0) to end of treatment (week 36) |
| Change in high-density lipoprotein (HDL) cholesterol | From baseline (week 0) to end of treatment (week 36) |
| Change in low-density lipoprotein (LDL) cholesterol | From baseline (week 0) to end of treatment (week 36) |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1Safety and Efficacy of Once-weekly Subcutaneous and Once-daily Oral NNC0487-0111 in Participants With Type 2 Diabetes - a Dose Finding StudyClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.